NYSE:BDX - Becton Dickinson and Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$235.34 -2.75 (-1.16 %)
(As of 10/22/2018 04:00 PM ET)
Previous Close$238.09
Today's Range$235.12 - $239.4750
52-Week Range$203.99 - $265.87
Volume941,949 shs
Average Volume1.16 million shs
Market Capitalization$63.70 billion
P/E Ratio24.82
Dividend Yield1.25%
Beta1.11
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Receive BDX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BDX
CUSIP07588710
Phone201-847-6800

Debt

Debt-to-Equity Ratio0.95
Current Ratio1.23
Quick Ratio0.81

Price-To-Earnings

Trailing P/E Ratio24.82
Forward P/E Ratio21.38
P/E Growth1.42

Sales & Book Value

Annual Sales$12.09 billion
Price / Sales5.21
Cash Flow$13.9419 per share
Price / Cash16.88
Book Value$56.89 per share
Price / Book4.14

Profitability

EPS (Most Recent Fiscal Year)$9.48
Net Income$1.10 billion
Net Margins4.73%
Return on Equity14.16%
Return on Assets5.39%

Miscellaneous

Employees41,933
Outstanding Shares267,560,000
Market Cap$63.70 billion

Becton Dickinson and (NYSE:BDX) Frequently Asked Questions

What is Becton Dickinson and's stock symbol?

Becton Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

How often does Becton Dickinson and pay dividends? What is the dividend yield for Becton Dickinson and?

Becton Dickinson and announced a quarterly dividend on Tuesday, July 24th. Stockholders of record on Friday, September 7th will be paid a dividend of $0.75 per share on Friday, September 28th. This represents a $3.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date is Thursday, September 6th. View Becton Dickinson and's Dividend History.

How were Becton Dickinson and's earnings last quarter?

Becton Dickinson and Co (NYSE:BDX) posted its earnings results on Thursday, August, 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.86 by $0.05. The medical instruments supplier earned $4.28 billion during the quarter, compared to analysts' expectations of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The business's revenue for the quarter was up 41.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.46 earnings per share. View Becton Dickinson and's Earnings History.

When is Becton Dickinson and's next earnings date?

Becton Dickinson and is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Becton Dickinson and.

How can I listen to Becton Dickinson and's earnings call?

Becton Dickinson and will be holding an earnings conference call on Tuesday, November 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What guidance has Becton Dickinson and issued on next quarter's earnings?

Becton Dickinson and updated its FY18 earnings guidance on Thursday, August, 2nd. The company provided EPS guidance of $10.95-11.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.98.

What price target have analysts set for BDX?

14 analysts have issued twelve-month target prices for Becton Dickinson and's stock. Their predictions range from $175.00 to $290.00. On average, they anticipate Becton Dickinson and's share price to reach $255.1429 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price. View Analyst Price Targets for Becton Dickinson and.

What is the consensus analysts' recommendation for Becton Dickinson and?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton Dickinson and in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Becton Dickinson and.

Who are some of Becton Dickinson and's key competitors?

Who are Becton Dickinson and's key executives?

Becton Dickinson and's management team includes the folowing people:
  • Mr. Vincent A. Forlenza, Chairman & CEO (Age 65)
  • Mr. Thomas E. Polen Jr., Pres (Age 45)
  • Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 61)
  • Mr. Alexandre Conroy, Pres of Worldwide Medication & Procedural Solutions (Age 55)
  • Mr. James W. Borzi, Exec. VP of Global Operations & Chief Supply Chain Officer (Age 55)

Who are Becton Dickinson and's major shareholders?

Becton Dickinson and's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.30%), Cornerstone Wealth Management LLC (0.24%), Waverton Investment Management Ltd (0.18%), Bristol John W & Co. Inc. NY (0.11%), Douglass Winthrop Advisors LLC (0.10%) and Atalanta Sosnoff Capital LLC (0.10%). Company insiders that own Becton Dickinson and stock include Alexandre Conroy, David F Melcher, Ellen R Strahlman, Gary M Cohen, James W Borzi, Jeffrey S Sherman, John E Gallagher, Linda M Tharby, Nabil Shabshab, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr and Timothy M Ring. View Institutional Ownership Trends for Becton Dickinson and.

Which institutional investors are selling Becton Dickinson and stock?

BDX stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, State of Alaska Department of Revenue, Eastern Bank, Texas Permanent School Fund, Saratoga Research & Investment Management, Bristol John W & Co. Inc. NY, Gillespie Robinson & Grimm Inc. and Sumitomo Mitsui Asset Management Company LTD. Company insiders that have sold Becton Dickinson and company stock in the last year include Alexandre Conroy, James W Borzi, John E Gallagher, Nabil Shabshab, Thomas E Polen Jr and Timothy M Ring. View Insider Buying and Selling for Becton Dickinson and.

Which institutional investors are buying Becton Dickinson and stock?

BDX stock was bought by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, Bank of Montreal Can, James Hambro & Partners, Calamos Advisors LLC, Waverton Investment Management Ltd, First Hawaiian Bank, Aperio Group LLC and Tower View Investment Management & Research LLC. View Insider Buying and Selling for Becton Dickinson and.

How do I buy shares of Becton Dickinson and?

Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Becton Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $235.34.

How big of a company is Becton Dickinson and?

Becton Dickinson and has a market capitalization of $63.70 billion and generates $12.09 billion in revenue each year. The medical instruments supplier earns $1.10 billion in net income (profit) each year or $9.48 on an earnings per share basis. Becton Dickinson and employs 41,933 workers across the globe.

What is Becton Dickinson and's official website?

The official website for Becton Dickinson and is http://www.bd.com.

How can I contact Becton Dickinson and?

Becton Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.


MarketBeat Community Rating for Becton Dickinson and (NYSE BDX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  406 (Vote Outperform)
Underperform Votes:  494 (Vote Underperform)
Total Votes:  900
MarketBeat's community ratings are surveys of what our community members think about Becton Dickinson and and other stocks. Vote "Outperform" if you believe BDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel